30 closest matches · ranked by relevance
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Primary: Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0; 0 Participants
Non Small Cell Lung Cancer · ROS1 Proto Oncogene · Crizotinib
Primary: Independent Radiology Reviewed Overall Objective Response (ORR) — 88 Participants
Non-Small Cell Lung Cancer
Primary: Eastern Cooperative Oncology Group (ECOG) Quality of Life Score: ALK Treatment and ROS1 Sub-study Only — 35; 11; 43; 29 Participants
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
NSCLC · Crizotinib · ALK Gene Rearrangement or ROS1 Gene Rearrangement
Primary: Age: Line of Treatment — 62.3; 63.1; 56.5; 64.3 Years
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) — 16.6; 8.1 Months — p=<0.001
Lung Cancer, Nonsmall Cell
Primary: The Number of Participants With an Objective Tumor Response Rate — 3 participants
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Lung Neoplasms
Primary: Number of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Biomarker — 45; 1346; 21; 38 Participants
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) by Investigator Assessment — NA; 11.1 months — p=<0.0001
Non-Small-Cell Lung Carcinoma
Primary: Recommended Phase 2 Dose (RP2D) of Alectinib
Non-small Cell Lung Cancer · Lung Cancer · Advanced Malignancies
Primary: Progression-free Survival (PFS) — 24.016; 11.072; 16.821 months — p=<0.0001
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator — 10.9; 1.4 months — p=<0.001
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
Non Squamous Lung Cancer
Primary: Progression-Free Survival (PFS) Based on IRR — 10.9; 7.0 months — p=<0.0001
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase I — 0; 0; 0; 0 participants
Advanced Non-Small Cell Lung Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 94; 89 Participants
Non-Small Cell Lung Cancer
Primary: Primary Pharmacokinetics (PK) Parameters of of LDK378 After Daily Oral Dose: AUClast, AUC0-24h, AUCinf — 10100; 3940; 11100 ng*hr/mL
ALK-positive Advanced NSCLC
Primary: Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC) — 26.2 percentage of participants — p=0.0763
Non-small Cell Lung Cancer Metastatic · Targetable Oncogenes (EGFR, ALK, ROS1)
Primary: 1-year Frequency of Distant Failures (DF) After Stereotactic Body Radiation Therapy (SBRT) — 19 percentage of participants
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
Carcinoma · Non-Small-Cell Lung
Primary: Percentage of Participants With Confirmed Overall Objective Response (OR) as Per Independent Central Review (ICR) as Assessed by RECIST v1.1 — 42.3 Percentage of…
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Primary: Overall Response Rate (ORR) — 0; 3; 19; 2 Participants
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants